x
Filter:
Filters applied
- Focus on Sarcoidosis
- Hamzeh, NabeelRemove Hamzeh, Nabeel filter
- 2021 - 2023Remove 2021 - 2023 filter
Author
- Barkes, Briana Q1
- Baughman, Robert P1
- Beaumont, Jennifer L1
- Chen, Edward S1
- Chhabra, Divya1
- Culver, Daniel A1
- Fingerlin, Tasha E1
- Jacobson, Sean1
- Judson, Marc A1
- Lei, Zhe1
- Li, Li1
- Lin, Nancy W1
- Liu, Sucai1
- Lower, Elyse E1
- MacPhail, Kristyn1
- Maier, Lisa A1
- Mayer, Annyce S1
- Mroz, Margaret M1
- Preston, Sara1
- Restrepo, Clara I1
- Shivas, Tricha1
- Singh, Noopur1
- Sweiss, Nadera J1
- Valeyre, Dominique1
Keyword
- Sarcoidosis2
- Area under the curve1
- AUC1
- BAL1
- BeLPT1
- Beryllium lymphocyte proliferation test1
- Beryllium sensitization1
- BeS1
- Bronchoalveolar lavage1
- CBD1
- Chronic beryllium disease1
- Diffusing capacity for carbon monoxide1
- DLCO1
- FEV11
- Forced expiratory volume in 1 s1
- Forced vital capacity1
- FVC1
- Gene expression1
- Genomic biomarkers1
- Granulomatous lung disease1
- Health-related quality of life1
- Outcomes1
- Patient assessment1
- Pulmonary function1
- ROC1
Focus on Sarcoidosis
2 Results
- Original Research
The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP)
Respiratory MedicineVol. 196106819Published online: March 18, 2022- Marc A. Judson
- Recai Yucel
- Sara Preston
- Edward S. Chen
- Daniel A. Culver
- Nabeel Hamzeh
- and others
Cited in Scopus: 0Cutoffs for most of the phenotypic measures used to assess sarcoidosis distinguished groups of sarcoidosis patients with differing OIPs over the subsequent 6 months. The patients’ global assessment of their disease was the most accurate of these measures. - Research Article
Genomic biomarkers in chronic beryllium disease and sarcoidosis
Respiratory MedicineVol. 187106390Published online: April 5, 2021- Nancy W. Lin
- Lisa A. Maier
- Margaret M. Mroz
- Sean Jacobson
- Kristyn MacPhail
- Sucai Liu
- and others
Cited in Scopus: 1Background Previous gene expression studies have identified genes IFNγ, TNFα, RNase 3, CXCL9, and CD55 as potential biomarkers for sarcoidosis and/or chronic beryllium disease (CBD). We hypothesized that differential expression of these genes could function as diagnostic biomarkers for sarcoidosis and CBD, and prognostic biomarkers for sarcoidosis. Study Design/Methods We performed RT-qPCR on whole blood samples from CBD (n = 132), beryllium sensitized (BeS) (n = 109), and sarcoidosis (n = 99) cases and non-diseased controls (n = 97) to determine differential expression of target genes.